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Characteristics of newly diagnosed COPD patients treated
with triple inhaled therapy by general practitioners: a real
world Italian study
Fabiano Di Marco1, Pierachille Santus2, Silvia Terraneo1, Elena Peruzzi3, Elisa Muscianisi4, Claudio Ripellino5 and Valeria Pegoraro5
Factors predicting prescriptions of triple therapy were investigated in a large group of general practitioners in Italy. In the
population treated by identiﬁed general practitioners, a cohort of newly diagnosed chronic obstructive pulmonary disease patients
was extracted from IMS Health Longitudinal Database during the period 2010–2013. From the diagnosis, 1-year follow-up was
evaluated. Thirty-two thousand forty-six newly diagnosed chronic obstructive pulmonary disease patients were evaluated (57.7%
male, mean age 67 years). During 2 years prior to diagnosis less than 13% of patients were requested with a pulmonology
evaluation and less than 5% with a spirometry; 65.1% cases were prescribed with a respiratory drug, which in 9.6% of cases was
inhaled corticosteroid/long-acting β2-agonist ﬁxed-dose combination. Two thousand and twenty eight patients (6.3% of the newly
diagnosed chronic obstructive pulmonary disease patients) were treated with triple therapy during the ﬁrst year of follow-up,
whose 858 (42.3%) starting immediately, and 762 (37.6%) following an initial treatment with inhaled corticosteroid/long-acting β2-
agonist ﬁxed-dose combination. Being older, being requested with pulmonologist evaluation or spirometry, being prescribed with a
inhaled corticosteroid/long-acting β2-agonist ﬁxed-dose combination at diagnosis resulted independent predictors of triple therapy
use.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable disease, characterized by persistent
airﬂow limitation that is usually progressive and associated with
an enhanced chronic inﬂammatory response to noxious particles
or gases in the airways and lungs. Exacerbations and comorbid-
ities contribute to the overall severity of patients.1, 2 The
destruction of lung parenchyma, increased by subtended
inﬂammatory processes, leads to loss of alveolar attachments to
the small airways and decreases lung elastic recoil; in turn, these
changes diminish the ability of the airways to remain opened
during expiration.3 COPD management is a major healthcare
problem, and numerous recommendations/guidelines were cre-
ated to increase appropriateness hence to address the unmet
need of patients remaining symptomatic, so to improve patients’
beneﬁt and reduce exacerbations risk.3, 4 International recom-
mendations, such as the GOLD document, and national guidelines
such as the ones provided by Agenas (Italian National Agency for
Regional Health Care Services), provide guidance to physicians in
treating COPD.4 Once COPD is diagnosed and its severity is
established, pharmacological treatment aims primarily to improve
dyspnea and quality of life, to prevent disease progression and
exacerbations, and to reduce mortality.5 Inhaled long-acting
bronchodilator therapy consists of long-acting β2 agonists
(LABAs), and/or long-acting muscarinic antagonists (LAMAs).6–9
The choice within each pharmacological class relies on the
availability and cost of the medication, and on the patient’s
response, strictly linked to severity of symptoms, airﬂow limitation
and rate and severity of exacerbations.3 Inhaled corticosteroids
(ICS) are usually added as anti-inﬂammatory agents in case of
exacerbation,10–13 but, in the ﬁxed association with LABA, they
have recently been demonstrated as less effective in moderate-
severe patients if compared to LAMA/LABA association in terms of
prevention of exacerbations.14 The current GOLD strategy docu-
ment recommends that the use of ICS is reserved for patients with
severe or very severe airﬂow limitation and/or ≥2 exacerbations
per year (GOLD groups C and D).5 This recommendation is based
on data from available studies, which indicated that patients with
a history of frequent exacerbations were more likely to beneﬁt
from ICS treatment. Provided the availability of new compounds,
during latter years, the pharmacological treatment of COPD
moved toward a more personalized approach, such as targeting
the eosinophils, the asthma and COPD overlap syndrome or the
so-called phenotype of the frequent exacerbator,15 and bringing
triple ICS/LABA/LAMA therapy to phase III.16, 17
Nevertheless, despite GOLD recommendations and even more
recent evidences underlining the efﬁcacy of LABA/LAMA FDC vs.
ICS/LABA ﬁx dose combination (FDC),14, 18 and despite a clear
identikit of severe COPD patient possibly beneﬁtting from
adequate triple therapy with ICS/LABA/LAMA, ICS and ICS/LABA
FDCs are often prescribed in the early stage of the disease.19, 20
Even if national recommendation in Italy suggest general
practitioner (GP)/specialist interaction, currently GPs are allowed
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to manage both the diagnosis (requesting spirometry or, in limited
cases, performing spirometry themselves), and the treatment of
COPD, with the only exception of the prescription of LABA/LAMA
FDCs, and roﬂumilast which need currently specialists’ indication.
The aim of the present study was to describe newly diagnosed
COPD patients according to their characteristics observed during 2
years prior to diagnosis and to identify factors that could predict
progression to triple therapy in the ﬁrst year after diagnosis in a
real-life context of GPs setting in Italy.
RESULTS
From the analysis of IMS Health LPD database, 32,046 newly
diagnosed COPD patients have been found, whose 2028 (6.3%)
have been treated with triple inhaled therapy in the year of follow-
up.
Feature of overall population
Characteristics of the overall cohort are shown in Table 1. The
majority of patients were male, with a mean age of 67 years, and
the majority of them expressing comorbidities (94.0%): as
expected, a high rate of cardiovascular diseases (65.0%) and
diabetes (16.8%), but also anxiety, and depression were found (6.3
and 5.8%, respectively). The registration of smoking history was
low, since in more than one out of four patients this information
was not collected. Moreover, more than one out of four patients
presented with obesity (i.e., BMI≥ 30 Kg/m2, Table 1, information
registered in 76.4% of cases). In the 2 years before diagnosis (i.e.,
pre-selection period), less than 13.0% of patients were requested
with a pulmonology evaluation and less than 5% of the patients
were requested with a spirometry. It is noteworthy that the same
approach was used also for patients treated with at least one
respiratory drug in the 2 years prior to diagnosis (65.1%), since
more than 80.0% were not requested a specialist evaluation nor a
spirometry (Table 1). Three-thousand sixty-nine patients have
been treated during the 2-year period before diagnosis with ICS/
LABA FDC (9.6% of the overall population, and 14.7% of patients
prescribed with any therapy, Table 1).
Features of patients treated with triple therapy
At the end of the ﬁrst year of follow-up period, 2028 patients
(6.3% of the newly diagnosed COPD patients) were treated with
triple therapy, whose 858 (42.3%) starting immediately at the time
of diagnosis, while 762 (37.6%) following an initial treatment with
ICS/LABA FDC. Mean time to triple therapy since ﬁrst COPD
diagnosis was estimated in 61 ± 91 days, with median time of
14 days.
Results from the comparison between patients initiated to triple
therapy within 1 year since the ﬁrst diagnosis and those who did
not are shown in Table 2. Patients prescribed with triple therapy
resulted on average 5 years older, more frequently male, and
affected by one or more comorbidities. As described in Table 2,
COPD symptoms frequency varied a lot accordingly with being
Table 1. Features of newly diagnosed COPD patients (overall
population n= 32,046)
Feature
Age, mean± SD, years 67± 15
<40 years, n (%) 1452 (4.5%)
≥80 years, n (%) 7199 (22.5%)
Female, n (%) 13558 (42.3%)
BMI, mean± SD, Kg/m2 27.5± 5.3
BMI< 18.5, n (%) 510 (2.4%)
BMI≥ 30, n (%) 5853 (27.5%)
Smoking habit missing, n (%) 8832 (27.6%)
Current smokers, n (%) 8004 (25.0%)
Comorbidities
None, n (%) 1940 (6.0%)
Cardiovascular disease, n (%) 20834 (65.0%)
Diabetes, n (%) 5397 (16.8%)
Osteoporosis, n (%) 3653 (11.4%)
Anxiety, n (%) 2009 (6.3%)
Depression, n (%) 1851 (5.8%)
Anemia, n (%) 908 (2.8%)
Reported respiratory symptoms1, n (%) 11,885 (37.1%)
Hospitalization in respiratory ward1, n (%) 248 (0.8%)
Pulmonology visit request1, n (%) 4149 (12.9%)
With spirometry, n (%) 2538 (61.2%)
Spirometry request1, n (%) 1473 (4.6%)
Respiratory treatment (any)1, n (%) 20,859 (65.1%)
Without pulmonology visit, n (%) 17,250 (82.7%)
Without spirometry, n (%) 17,515 (84.0%)
Respiratory treatment with ICS/LABA FDC1, n (%) 3069 (9.6%)
ICS/LABA FDC inhaled corticosteroid/long-acting β2 agonist ﬁxed-dose
combination, SD standard deviation
1 In the pre-selection period (i.e., 2 years before the diagnosis of COPD)
Table 2. Comparison between patients prescribed or not with triple
therapy
Treated with
triple therapy
(n= 2028)
Not treated with
triple therapy
(n= 30018)
P
Age, mean± SD, years 72± 11 67± 15 <0.001
Female, n (%) 789 (38.9%) 12769 (42.5%) 0.001
BMI, mean± SD, Kg/m2 27.9± 5.5 27.4± 5.3 0.013
Current smokers, n (%) 372 (25.9%) 7632 (35.0%) <0.001
Comorbidities1, n (%) 1555 (76.7%) 21365 (71.2%) <0.001
None, n (%) 1779 (2.9%) 161(3.7%) 0.002
CV Diseases, n (%) 19,394 (31.4%) 1440 (33.1%) 0.015
Depression, n (%) 1716 (2.8%) 135 (3.1%) 0.200
Osteoporosis, n (%) 3412(5.5%) 241(5.5%) 0.938
Anemia, n (%) 855(1.4%) 53 (1.2) 0.371
Diabetes, n (%) 5024(8.1%) 373 (8.6%) 0.286
Anxiety states, n (%) 1893(3.0%) 116 (2.7%) 0.145
COPD symptoms2, n
(%)
1153 (56.6%) 10732 (35.8%) <0.001
Spirometry request2,
n (%)
580 (28.6%) 3431 (11.4%) <0.001
Pulmonology visit
request2, n (%)
665 (32.8%) 3484 (11.6%) <0.001
Respiratory treatment2,
n (%)
1592 (78.5%) 19,267 (64.2%) <0.001
ICS/LABA FDC at
diagnosis, n (%)
762 (37.6%) 2307 (7.8%) <0.001
ICS/LABA FDC inhaled corticosteroid/long-acting β2 agonist ﬁxed-dose
combination, SD standard deviation
1 Patients with at least one comorbidity among the following ones:
cardiovascular diseases, diabetes, osteoporosis, anxiety, depression, and
anemia
2 In the pre-selection period (i.e. 2 years before the diagnosis of COPD)
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prescribed with triple therapy, with 56.8% and 35.7% of patients
with at least one COPD symptoms in the subgroup of patients that
went to triple therapy, and in the subgroup of patients who
didnot, respectively (P < 0.001, Table 2). In the 2 years before
diagnosis, the approach of the GPs resulted different in the two
subgroups, since more patients initiated to triple therapy had at
least one pulmonologist visit, one spirometry, or have been
treated with a respiratory treatment (P < 0.001 for all comparisons,
Table 2). Also, the proportions of patients who had at least one
ICS/LABA FDC prescription at COPD diagnosis resulted very
different: among patients prescribed with triple therapy, 762
(37.6%) had at least one ICS/LABA FDC prescription in comparison
with 7.7% among those who were not prescribed with triple
therapy (P < 0.001).
Multivariate cox regression model showed a statistically
signiﬁcant association between triple therapy and all the studied
covariates included in the model, with none of them excluded
according to the stepwise approach adopted (Table 3). Being so,
male patients, elderly patients and patients requested with a
pulmonology visit or just a spirometry were more likely prescribed
with triple therapy than other patients. Moreover, patients who
presented COPD symptoms during the pre-selection period were
more likely prescribed with triple therapy, whereas comorbidities
presence had the opposite effect. Furthermore, being prescribed
with a ICS/LABA FDC at the ﬁrst COPD diagnosis seemed to be a
strong predictor of being prescribed with triple therapy within 1
year since diagnosis, with a HR of 5.10 (95% CI: 4.65–5.60, Table 3).
DISCUSSION
Main ﬁndings
In this large GPs setting, following results were found: (1)
symptomatic, males, older patients, patients with less comorbid-
ities and patients prescribed with a pulmonology visit or just a
spirometry were more likely prescribed with triple therapy; (2)
prescription of ICS/LABA FDC at the time of diagnosis and older
age seemed to be the strongest predictors for triple therapy use.
(3) in the 2 years before the diagnosis few patients were requested
with a pulmonology evaluation or a spirometry, even if treated
with a respiratory drugs.
Interpretation of ﬁndings in relation to previously published work
Our newly diagnosed COPD patients’ cohort presents demo-
graphic characteristics similar to those found in a cohort of
patients collected in an analog real world evidence study
conducted in UK,21 with both studies describing a mean age of
about 67 years and a mean BMI of 27 kg/m2 for patients at their
ﬁrst COPD diagnosis. Results in terms of comorbidities are in line
with those found by the INDACO study,22 reporting a high
prevalence of comorbidities among COPD patients, with more
than 80% presenting with at least one comorbidity. Patients with
recorded symptoms before being diagnosed with COPD repre-
sented 37%. Considering that symptomatology recorded in the
database is not mandatory unless leading to a prescription,
specialist visit or exam request, this proportion should be
regarded as quite high. In addition, it should be kept in mind
that the analyzed setting is the one of GPs. Pulmonologist visit
including FEV1 evaluation were found just in a small group of
patients. Pulmonologists visits and FEV1 evaluations could
increase the probability of a better management as well as to a
reduced delay in proper diagnosis. In addition patients that had at
least one respiratory treatment before diagnosis, represented
65.1% of the total population. Delay in COPD diagnosis by GPs has
been conﬁrmed also in previous studies. When comparing results
about the proportion of patients prescribed with ICS/LABA FDC at
the time of the ﬁrst COPD diagnosis, results from the present
study showed a approximate 10% lower proportion than the one
found in the above mentioned UK study (approximately 43%).21 It
should be taken in account that for the UK study is not speciﬁed
whether LABA and ICS combinations are ﬁxed, extemporaneous or
both, while in the present study only ﬁxed combinations have
been evaluated. Nevertheless, when evaluating the proportion of
patients that within 1 year progress to triple therapy among those
prescribed with ICS/LABA FDC at the time of ﬁrst diagnosis, the
present study revealed a higher percentage (25% coming from
762 patients over 3069 prescribed with ICS/LABA FDC vs. 17%
from UK study). Proportions become more similar when compar-
ing the 25% of patients going to triple therapy within 1 year (Italy),
with the 24% of patients going to triple therapy within 2 years
(UK), leading to the consideration that, probably, Italian GPs are
more cautious at prescribing ICS/LBA FDC as a ﬁrst line therapy,
but at the same time the step up in therapy happens faster when
compared to the English setting. The rapidity Italian GPs escalate
therapy as observed in the present study, could be related to the
fact that ICS/LABA are prescribed as ﬁxed dose combinations.
The reduced likelihood of being prescribed with triple therapy
observed for patients affected by other comorbidities is an
interesting ﬁnding that should be contextualized in the GPs’
setting: research and guidelines on the management of long-term
conditions have routinely focused on single diseases,23 while
patients with comorbidities are usually excluded from randomized
controlled trials.24 This has led to individual disease management
rather than a more holistic approach that, on the other hand,
should be the approach adopted by GPs. The more chronic
conditions a patient has, the more medications they are likely to
be prescribed.25, 26 Multiple therapies commonly lead to drug
disease interaction and drug–drug interactions:17, 27, 28 these
issues, as well as the fear of adverse drug reactions, are the factors
probably preventing GPs’ from prescribing triple therapy to
patients affected by comorbidities, possibly due to the conception
of COPD as less important than other chronic disease (e.g.,
cardiovascular disease or diabetes). However, drugs for COPD are
inhaled, thus much less likely to cause systemic adverse effects
and drug interactions than systemic ones.
Table 3. Multivariate cox regression model to predict prescription of
triple therapy
Hazard ratio 95% Conﬁdence interval
Female (vs. male) 0.81 0.74–0.89
Age classes
<40 1.00
40–50 2.99 1.58–5.67
50–60 4.70 2.56–8.65
60–70 7.57 4.16–13.79
70–80 9.77 5.37–17.79
≥80 9.86 5.41–17.98
COPD symptoms1 1.54 1.40–1.70
Comorbidities2 0.80 0.72–0.90
Pulmonology visit request1 1.98 1.76–2.24
Spirometry request1 1.26 1.12–1.43
ICS/LABA FDC at diagnosis 5.10 4.65–5.60
ICS/LABA FDC inhaled corticosteroid/long-acting β2 agonist ﬁxed-dose
combination
1 In the pre-selection period (i.e., 2 years before the diagnosis of COPD)
2 Patients with at least one comorbidity among the following ones:
cardiovascular diseases, diabetes, osteoporosis, anxiety, depression, and
anemia
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Strengths and limitations of this study
The large number of patients included in the analysis has to be
considered among the study strengths’, together with the
longitudinal nature of data collected, the generalizability of Italian
general practice population, and the usage of validated codes for
identifying COPD patients. Among study limitations, it should be
addressed that smoking habits information were not considered
since in the database data about this issue are not complete.
These data conﬁrm a study by Bryant et al.29 describing that
accurate detection of smoking habits occurs in less than two-
thirds of all patients, despite signiﬁcant investment to increase
GPs’ intervention for lifestyle risk factors, even if the possibility
that GPs discussed this aspect with their patients without
including it in the medical records cannot be ruled out. Moreover,
this kind of information in a real practice context could not be
reliable due to the fact that, being based on what patients report
to the GPs, they are self-reported measures, and it is known that
self-reported information about smoking status are biased.30 The
study was also limited by the lack of available information on FEV1
values, as well as hospitalizations and exacerbations, which would
have provided a more comprehensive picture of COPD patients’
management and would have allowed a stratiﬁcation by disease
severity. Nevertheless, results from a previous study using the
same source of data, where FEV1 was recorded to deﬁne disease
severity as per GOLD guidelines, suggest that the presence of FEV1
value does not constitute a bias: patients resulted to be
distributed among disease severity classes, with mild and
moderate patients accounting for about 80% of the cohort.31
Another limitation is the lack of spirometry assessment to
diagnose COPD: this approach is common for all “real life” studies,
currently proposed also to evaluate the effectiveness of new
treatments (Salford study). This bias, which should not affect the
interpretation of the results, is in line with the aim to evaluate the
behavior of GPs in real clinical practice. Then, “Chronic bronchitis”,
a condition different from COPD in the absence of obstruction,
was also included in the analysis, given the term often used as a
synonymous for COPD. Finally, the role of GPs is different in
several countries, condition which limits the external validity of
our study.
Implications for future research, policy, and practice
Even if there is an Italian document/guideline on COPD diagnosis
and treatment, the results of our study failed to demonstrate an
appropriate management of patients32 suffering from this disease.
In this respect, new campaigns of information are desirable:
following such an informative approach, a new study to evaluate
whether the approach to COPD has improved is needed, mainly in
terms of early diagnosis with spirometry, and appropriate
treatment and follow-up. Then, accessibility of spirometry in
primary care has to be facilitated.
Conclusions
In the studied population, the choice of treatment is driven by a
set of factors that include symptoms, general patients’ features as
well as functional and specialists evaluation. However, the
proportions of patients with a request for a specialist evaluation
or a spirometry are still very low. Even if the last version of GOLD
document gives a high level of importance to symptoms for the
choice of the treatment, the same document underline the
importance of spirometry to conﬁrm the diagnosis and to assess
the level of the ﬂow limitation. In this setting educational
programs should be implemented for GPs in order to optimize
the diagnosis treatment and follow up of patients with COPD.
METHODS
Data source
The data used in the present study were retrieved from the Italian General
Practitioners’ (GPs) IMS Health Longitudinal Patient Database (IMS Health
LPD) established in 1998 primarily to carry out epidemiologic studies and
to monitor drugs prescriptions and drug safety. The database is fed by a
constant representative doctors’ sample that agreed to take part to a
research panel, has been trained for data entry and uses standard patient
management software to collect data directly during the consultations.
The information, which is gathered continually and in real time allows
patients and doctors to be longitudinally monitored and includes
anonymous data about patients’ demographics, medical diagnoses, drug
prescriptions, hospital referrals, diagnostic investigations, and date of
death. Medical diagnoses and drugs prescriptions, both coded directly by
GPs, comply with the ninth edition of International Classiﬁcation of Disease
(ICD-9-CM), and the Anatomical Therapeutic and Chemical classiﬁcation
system, respectively. All medical records are linked together with a unique
encrypted patient code. In Italy, IMS Health LPD consists of a panel of
about 900 GPs homogenously distributed throughout the national
territory; it collects information about 1 million patients per year and it
is representative of the Italian general population. IMS Health LPD
database reliability has been recognized by the pharmaceutical industry
and medicine agencies.33
Ethics
The study was performed in accordance with Good Epidemiological
Practice guidelines. Ethics board approval was not required because the
data were not nominative and were collected retrospectively.
Cohort selection
Newly diagnosed COPD Cohort was selected in the period from 1 January
2010 to 31 December 2013, as patients with a COPD diagnosis, deﬁned as
“Chronic bronchitis”, “Emphysema” or “Chronic airway obstruction, not
elsewhere classiﬁed”. The presence of at least one registration within the
database of one of the above-mentioned ICD-9-CM codes was the only
criteria to deﬁne COPD diagnoses (i.e., not necessarily conﬁrmed by
spirometry). In order to identify the ﬁrst diagnosis, patients with a
diagnosis during the previous 3-year period were excluded from the
analysis. The date of the ﬁrst COPD diagnosis (i.e., index date) during the
selection period was set as the 1 years follow-up period start.
Variables analyzed during the pre-selection period
For each patient, information about COPD symptoms (see Appendix),
spirometry execution, respiratory treatments (see Appendix), comorbidities
(deﬁned by means of ICD-9 codes registrations), and pulmonologist visits
requests over a 2-year period before the ﬁrst COPD diagnosis (i.e., pre-
selection period) were collected and analyzed to characterize patients and
used as covariate in the analysis.
Follow-up and outcomes
Each cohort member was followed from the date of ﬁrst COPD diagnosis
until outcome onset (see below), censoring, i.e., death, emigration, or end of
follow-up (i.e., 12 months after the date of ﬁrst COPD diagnosis), whichever
date occurred earlier. Main outcome (i.e., triple therapy presence during
follow-up) was deﬁned as the presence of concomitant prescriptions of
LABA, LAMA, and ICS. Prescriptions were considered concomitant when the
lapse of time between them was less than 30 days. Time to triple therapy
was calculated as the difference, in days, between the date of the ﬁrst
prescription that deﬁned a triple therapy presence during the follow up
period, and the ﬁrst COPD diagnosis date.
Statistical analysis
Newly diagnosed COPD patients were described in terms of demographic,
and clinical characteristics; qualitative variables were described using usual
statistical methodologies, which are frequencies and percentages, whereas
quantitative variables were described in terms of mean ± standard
deviation. Chi-square test was calculated to compare patients who
received triple therapy within 1 year since the ﬁrst COPD diagnosis to
patients who did not. Comparison was based on presence/absence of
respiratory treatments, spirometry execution, pulmonologist visit requests,
and COPD symptoms during the pre-selection period and presence/
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absence of at least one LABA/ICS FDC prescription at the ﬁrst COPD
diagnosis. To evaluate the potential association between triple therapy and
factors that could inﬂuence the likelihood of being prescribed triple, age,
sex, presence/absence respiratory symptoms before diagnosis, comorbid-
ities, pulmonology visit, spirometry, and prescriptions LABA/ICS FDC at the
ﬁrst COPD diagnosis were considered in both univariate and multivariate
Cox regression models. For multivariate models, each variable had been
retained in the ﬁnal model according to a stepwise approach. A p-value
below than 0.15 was the cutoff. For all the above-mentioned analysis, p-
values below than 0.05 had been considered as statistically signiﬁcant.
Data availability
The data that support the ﬁndings of this study are available from
QuintilesIMS, but restrictions apply to the availability of these data, which
were used under license for the current study, and so are not publicly
available. Data are, however, available from the corresponding author
upon reasonable request and with permission of QuintilesIMS.
ACKNOWLEDGEMENTS
This study and the article processing charges were supported by an unrestricted
grant from Novartis Farma Italy, which was not responsible for the study, data
analysis, data interpretation, or manuscript writing. QuintilesIMS was responsible for
data extraction, data analysis, and editorial assistance.
AUTHOR CONTRIBUTIONS
F.D.M., P.S., S.T., E.P., E.M., C.R., and V.P. conceived and designed the study. E.P., C.R.,
and V.P. analyzed the data. F.D.M., S.T., and P.S. wrote the ﬁrst draft of the paper,
which was modiﬁed up to the ﬁnal version submitted after a critical revision of all
authors.
ADDITIONAL INFORMATION
Supplementary Information accompanies the paper on the npj Primary Care
Respiratory Medicine website (doi:10.1038/s41533-017-0051-9).
Competing interests: Ripellino and Pegoraro are employed at QuintilesIMS at the
time of submission. Peruzzi and Muscianisi are employed at Novartis Farma Italy at
the time of submission. Santus has received ﬁnancial support for research from
Pﬁzer, Almirall, Chiesi Farmaceutici, and AirLiquide. He has received honoraria for
lectures at national meetings from Chiesi Farmaceutici, Novartis, Zambon Italia,
AstraZeneca, Almirall,GlaxoSmithKline, Boehringer Ingelheim, Menarini, and
Malesci-Guidotti. He has served as consultant for Zambon Italia, AstraZeneca,
Novartis, Chiesi Farmaceutici, and Boehringer Ingelheim. Di Marco has received
honoraria for lectures at national and international meetings from Almirall,
AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dompe, Guidotti/Malesci,
GlaxoSmithKline, Menarini, Novartis, and Zambon. He has served as consultant for
AstraZeneca, Chiesi Farmaceutici, Novartis, and Zambon. He has received ﬁnancial
support for research from Novartis. Terraneo declares no competing ﬁnancial
interest.
Ethical approval: This article does not contain any new studies with human or
animal subjects performed by any of the authors.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. Donaldson, G. C., Seemungal, T. A. R., Bhowmik, A. & Wedzicha, J. A. Relationship
between exacerbation frequency and lung function decline in chronic obstruc-
tive pulmonary disease. Thorax 57, 847–852 (2002).
2. Schwab, P. et al. Impact of comorbid conditions in COPD patients on health care
resource utilization and costs in a predominantly medicare population. Int. J.
Chron. Obstruct. Pulmon. Dis. 12, 735–744 (2017).
3. GOLD. Global strategy for diagnosis, management and prevention of COPD-2015.
http://www.goldcopd.org/ (2015).
4. Ambrosino, N. et al. Broncopneumopatia Cronica Ostruttiva. Linee guida nazionali
di riferimento per la prevenzione e la terapia. AGENAS Agenzia Nazionale per i
Servizi Sanitari. (2010).
5. Calverley, P. et al. Combined salmeterol and ﬂuticasone in the treatment of
chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361,
449–456 (2003).
6. Jones, P. W., Willits, L. R., Burge, P. S. & Calverley, P. M. A. Inhaled steroids in
obstructive lung disease in Europe study investigators. Disease severity and the
effect of ﬂuticasone propionate on chronic obstructive pulmonary disease
exacerbations. Eur. Respir. J. 21, 68–73 (2003).
7. Mahler, D. A. et al. Effectiveness of ﬂuticasone propionate and salmeterol
combination delivered via the diskus device in the treatment of chronic
obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 166, 1084–1091
(2002).
8. Jochmann, A. et al. General practitioner’s adherence to the COPD GOLD guide-
lines: baseline data of the Swiss COPD Cohort study. Swiss Med. Wkly. https://smw.
ch/article/doi/smw.2010.13053 (2010).
9. Montuschi, P. & Ciabattoni, G. Bronchodilating drugs for chronic obstructive
pulmonary disease: current status and future trends. J. Med. Chem. 58, 4131–4164
(2015).
10. National Institute for Health and Clinical Eccellence. NICE Clinical Guideline 101.
http://www.nice.org.uk/guidance/cg101. (2014).
11. American Thoracic Society/European Respiratory Society. Standards for diagnosis
and management of patients with COPD. http://www.thoracic.org/clinical/copd-
guidelines/resources/copddoc.pdf. (2013).
12. Osthoff, M., Jenkins, C. & Leuppi, J. Chronic obstructive pulmonary disease–a
treatable disease. Swiss Med. Wkly. 143, 1–8. (2013).
13. Fuso, L., Mores, N., Valente, S., Malerba, M. & Montuschi, P. Long-acting beta-
agonists and their association with inhaled corticosteroids in COPD. Curr. Med.
Chem. 20, 1477–1495 (2013).
14. Sannigrahi, S. et al. LANTERN: a randomized study of QVA149 versus salmeterol/
ﬂuticasone combination in patients with COPD. Int. J. Chron. Obstruct. Pulmon.
Dis. 10, 1015–1026 (2015).
15. Lange, P., Halpin, D. M., O’Donnell, D. E. & MacNee, W. Diagnosis, assessment, and
phenotyping of COPD: beyond FEV1. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 3–12
(2016).
16. Montuschi, P., Malerba, M., Santini, G. & Miravitlles, M. Pharmacological treatment
of chronic obstructive pulmonary disease: from evidence-based medicine to
phenotyping. Drug Discov. Today 19, 1928–1935 (2014).
17. Montuschi, P., Malerba, M., Macis, G., Mores, N. & Santini, G. Triple inhaled therapy
for chronic obstructive pulmonary disease. Drug Discov. Today 21, 1820–1827
(2016).
18. Wedzicha, J. A. et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone
for COPD. N. Engl. J. Med. 374, 2222–2234 (2016).
19. Suissa, S. & Barnes, P. J. Inhaled corticosteroids in COPD: the case against. Eur.
Respir. J. 34, 13–16 (2009).
20. Cazzola, M. & Molimard, M. The scientiﬁc rationale for combining long-acting β2-
agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 23, 257–267
(2010).
21. Wurst, K. E., Punekar, Y. S. & Shukla, A. Treatment evolution after COPD diagnosis
in the UK primary care setting. PLoS One 9, 1–7 (2014).
22. Fumagalli, G. et al. INDACO project: COPD and link between comorbidities, lung
function and inhalation therapy. Multidiscip. Respir. Med. 10, 1–6 (2015).
23. Violan, C. et al. Prevalence, determinants and patterns of multimorbidity in pri-
mary care: a systematic review of observational studies. PLoS ONE. doi:10.1371/
journal.pone.0102149 (2014).
24. Barnett, K. et al. Epidemiology of multimorbidity and implications for health care,
research, and medical education: a cross-sectional study. Lancet 380, 37–43
(2012).
25. Taylor, A. W. et al. Multimorbidity-not just an older person’s issue. Results from an
Australian biomedical study. BMC Public Health 10, 1–10 (2010).
26. Lehnert, T. et al. Review: health care utilization and costs of elderly persons with
multiple chronic conditions. Med. Care Res. Rev. 68, 387–420 (2011).
27. Dumbreck, S. et al. Drug-disease and drug-drug interactions: systematic exam-
ination of recommendations in 12 UK national clinical guidelines. BMJ 350, h949
(2015).
28. Moffat, K. & Mercer, S. W. Challenges of managing people with multimorbidity in
today’s healthcare systems. BMC Fam. Pract. 16, 1–3 (2015).
29. Bryant, J. et al. Is identiﬁcation of smoking, risky alcohol consumption and
overweight and obesity by general practitioner’s improving? A comparison over
time. Fam. Pract. 32, 664–671 (2015).
30. Avanzini, F. et al. Improving cardiovascular prevention in general practice: results
of a comprehensive personalized strategy in subjects at high risk. Eur. J. Prev.
Cardiol. 23, 947–955 (2016).
31. Katz, P. & Pegoraro, V. L’utilizzo dei corticosteroidi nei pazienti con la broncop-
neumopatia cronica ostruttiva: aspetti epidemiologici ed economici. Farm. e
Percorsi Ter. 10, 139–148 (2009).
COPD new patients and triple therapy: a RWE Italian study
F Di Marco et al.
5
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2017)  51 
32. Bettoncelli, G. et al. The clinical and integrated management of COPD: an ofﬁcial
document of AIMAR (Interdisciplinary Association for Research in Lung Disease),
AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of
Respiratory Medicine), SIMG (Italian Society of General Medicine). Multidiscip.
Respir. Med. 9, 1–16 (2014).
33. AIFA. L’uso dei farmaci in Italia-Rapporto OsMed 2012. Osservatorio nazionale
dell’impiego dei medicinali. Rapporto Nazionale 2012. http://www.aifa.gov.it/con-
tent/luso-dei-farmaci-italia-rapporto-osmed-2012 (2012).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2017
COPD new patients and triple therapy: a RWE Italian study
F Di Marco et al.
6
npj Primary Care Respiratory Medicine (2017)  51 Published in partnership with Primary Care Respiratory Society UK
